Show simple item record

dc.contributor.authorPaonessa, Joseph R.
dc.contributor.authorBrennan, Thomas
dc.contributor.authorPimentel, Marco
dc.contributor.authorSteinhaus, Daniel
dc.contributor.authorFeng, Mengling
dc.contributor.authorCeli, Leo A.
dc.date.accessioned2021-11-01T14:33:52Z
dc.date.available2021-11-01T14:33:52Z
dc.date.issued2015-12-01
dc.identifier.urihttps://hdl.handle.net/1721.1/136865
dc.description.abstractIntroduction Limited information exists on the etiology, prevalence, and significance of hyperdynamic left ventricular ejection fraction (HDLVEF) in the intensive care unit (ICU). Our aim in the present study was to compare characteristics and outcomes of patients with HDLVEF with those of patients with normal left ventricular ejection fraction in the ICU using a large, public, deidentified critical care database. Methods We conducted a longitudinal, single-center, retrospective cohort study of adult patients who underwent echocardiography during a medical or surgical ICU admission at the Beth Israel Deaconess Medical Center using the Multiparameter Intelligent Monitoring in Intensive Care II database. The final cohort had 2867 patients, of whom 324 had HDLVEF, defined as an ejection fraction >70 %. Patients with an ejection fraction <55 % were excluded. Results Compared with critically ill patients with normal left ventricular ejection fraction, the finding of HDLVEF in critically ill patients was associated with female sex, increased age, and the diagnoses of hypertension and cancer. Patients with HDLVEF had increased 28-day mortality compared with those with normal ejection fraction in multivariate logistic regression analysis adjusted for age, sex, Sequential Organ Failure Assessment score, Elixhauser score for comorbidities, vasopressor use, and mechanical ventilation use (odds ratio 1.38, 95 % confidence interval 1.039–1.842, p =0.02). Conclusions The presence of HDLVEF portended increased 28-day mortality, and may be helpful as a gravity marker for prognosis in patients admitted to the ICU. Further research is warranted to gain a better understanding of how these patients respond to common interventions in the ICU and to determine if pharmacologic modulation of HDLVEF improves outcomes.en_US
dc.publisherBioMed Centralen_US
dc.relation.isversionofhttps://doi.org/10.1186/s13054-015-1012-8en_US
dc.rightsCreative Commons Attributionen_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en_US
dc.sourceBioMed Centralen_US
dc.titleHyperdynamic left ventricular ejection fraction in the intensive care uniten_US
dc.typeArticleen_US
dc.identifier.citationCritical Care. 2015 Dec 01;19(1):288en_US
dc.contributor.departmentMassachusetts Institute of Technology. Institute for Medical Engineering & Science
dc.identifier.mitlicensePUBLISHER_CC
dc.eprint.versionFinal published versionen_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dc.date.updated2021-08-08T03:30:39Z
dc.language.rfc3066en
dc.rights.holderPaonessa et al.
dspace.date.submission2021-08-08T03:30:39Z
mit.licensePUBLISHER_CC
mit.metadata.statusAuthority Work and Publication Information Needed


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record